Two Sigma Investments, LP Aligos Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.35 - $1.07 $28 - $87	82 Added 0.44%	18,706 $6,000
Q4 2023 Feb 14, 2024	SELL	$0.56 - $0.8 $2,408 - $3,440	-4,300 Reduced 18.76%	18,624 $12,000
Q3 2023 Nov 14, 2023	SELL	$0.71 - $1.06 $4,443 - $6,634	-6,259 Reduced 21.45%	22,924 $17,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $24,629 - $37,636	-27,674 Reduced 48.67%	29,183 $28,000
Q1 2023 May 15, 2023	SELL	$0.87 - $2.11 $29,198 - $70,813	-33,561 Reduced 37.12%	56,857 $49,000
Q4 2022 Feb 14, 2023	SELL	$0.89 - $28.0 $30,267 - $952,224	-34,008 Reduced 27.33%	90,418 $85,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.5 $75,245 - $1.95 Million	-70,986 Reduced 36.33%	124,426 $137,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $7,571 - $15,579	-7,280 Reduced 3.59%	195,412 $236,000
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $281,471 - $1.65 Million	135,323 Added 200.87%	202,692 $436,000
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $258,231 - $397,918	-22,494 Reduced 25.03%	67,369 $800,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $1.31 Million - $1.59 Million	89,863 New	89,863 $1.39 Million

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.